Comparison of Five TSH-Receptor Antibody Assays in Graves’ disease: results from an observational pilot study

BMC Endocrine Disorders

Table 3 AUC for GD diagnosis and relapse compared to GREAT score and refitted with new TRAb’s^b

	DIAGNOSIS				GD RELAPSE PREDICTION
Discriminator	Sensitivity [%]	Specificity [%]	AUC	95% CI	AUC	95% CI	Improved AUC	95% CI
GREAT score without routine TRAb					0.57	(0.43–0.71)
GREAT score with routine TRAb^a					0.69	(0.56–0.81)
							GREAT score with new assay
BRAHMS TRAK	86.7	93.7	0.96	(0.91–0.99)	0.71	(0.57–0.86)	0.67	(0.53–0.81)
IMMULITE TSI	94.0	91.7	0.97	(0.92–0.99)	0.69	(0.54–0.84)	0.66	(0.53–0.79)
EliA anti-TSH-R
≥ 2.9 U/L	79.5	93.7	0.95	(0.90–0.98)	0.68	(0.52–0.83)	0.68	(0.54–0.82)
> 3.3 U/L	71.1	97.9	0.95	(0.90–0.98)	0.68	(0.52–0.83)	0.68	(0.54–0.82)
RSR TRAb Fast	94.0	89.6	0.96	(0.91–0.99)	0.67	(0.50–0.83)	0.64	(0.50–0.78)
RSR-bioassay STIMULATION	81.9	87.5	0.90	(0.84–0.95)	0.62	(0.45–0.78)	0.62	(0.48–0.76)

Abbreviation: GREAT Graves’ Recurrent Events After Therapy, ROC AUC receiver operator curve, analysis under the curve, TRAb TSH-receptor autoantibodies
^aRecalculated for this cohort
^bROC AUC with 95% CI < 50% are regarded as worse than chance; 50–70% are regarded as clinically unsuitable; > 70% are deemed clinically relevant

ISSN: 1472-6823